A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Erlotinib (Primary) ; Pertuzumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 11 Jul 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.